The efficacy of Semax in the treatment of patients at different stages of ischemic stroke.

Reports clinical use of Semax across acute and rehabilitation phases of ischemic stroke, with improvements in neurological deficit scales attributed to neuroprotective and neurotrophic activity.

Investigated as a clinical (ischemic stroke patients) in the field of neuroscience research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.

Reports clinical use of Semax across acute and rehabilitation phases of ischemic stroke, with improvements in neurological deficit scales attributed to neuroprotective and neurotrophic activity.

Single-centre Russian clinical literature; methodology and blinding are limited and findings have not been confirmed in large international randomized trials.

• · PubMed: PMID 29798983 ↗
• · DOI: 10.17116/jnevro20181183261-68 ↗
• · PubMed search by title: pubmed.ncbi.nlm.nih.gov ↗
• · Google Scholar: scholar.google.com ↗